The Chinese government will add three dozen new drugs to its national insurance—including some big-selling foreign meds like Roche’s Herceptin, Celgene’s Revlimid and AstraZeneca’s Brilinta. The surprise? The move comes less than six months after China’s last coverage change. The not-so-surprising? Big price cuts.
More: To win blockbuster spots on China's coverage list, Big Pharma offers big discounts